Management discuses results from the Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on a conference call to be held on April 28 at 8 am. Webcast Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting
- CG Oncology’s Promising Phase 3 Data and Market Potential Justify Buy Rating
- CG Oncology initiated with a Sector Perform at Scotiabank
- Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities
- Buy Rating for CG Oncology, Inc. Driven by Promising Developments in Bladder Cancer Treatment